Pharma Companies With Consistent QoQ Sales Growth Over the Past Four Quarters

Senores Pharma Leads With Strong Double-Digit Growth

Senores Pharma continues to stand out among emerging pharma names, recording 18% QoQ growth in Q2 FY26. Over the last four quarters, the company has repeatedly delivered double-digit expansion.

Key growth drivers include:

• A rapidly expanding generic product portfolio
• Strong US market traction
• Efficient supply chain execution
• Improved capacity utilisation

This consistent growth trajectory positions Senores Pharma as one of the most stable outperformers in the mid-cap pharma space.

Zota Health Care Delivers Robust 24% QoQ Jump.

Zota Health Care reported a remarkable 24% QoQ increase in the latest quarter, with earlier quarters also showing sustained single- to double-digit growth.

The company’s performance has been driven by:

• Strong branded generics portfolio
• Improved domestic market penetration
• Higher contribution from chronic therapies

With a 35% spike in Q4 FY25, Zota remains one of the fastest-growing names in this category.

Granules India Maintains Consistent Momentum

Granules India continues to deliver steady performance with mid-to-high single-digit QoQ growth.

Growth factors include:

• Stable US formulations business
• Increased paracetamol and metformin demand
• Better operational efficiencies across manufacturing units

Its 19% growth in Q3 FY25 underscores the company’s ability to scale despite volatility in raw materials.

Other Consistent Performers

Several other pharma names have also shown sustained QoQ growth:

Caplin Point

• Delivered stable 2–5% QoQ growth
• A strong Latin American presence supports steady revenue visibility.

Dr Reddy’s Laboratories

• Posted modest 1–6% QoQ growth
• Supported by launches in the US and India

Windlas Biotech

• Delivered 4–6% steady QoQ expansion
• Continued traction in contract manufacturing

These companies have benefited from diversified portfolios, higher capacity utilisation, and stronger export performance.

Sector Outlook: Consistency Drives Confidence

Consistent QoQ sales growth across this set of companies highlights:

• Resilient domestic demand
• Improving product mix
• Strong export recovery
• Better operating leverage

With regulatory environments stabilising and global demand for generics rising, these companies are well positioned to sustain momentum in FY26.